Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | +3.57% | +17.35% | +48.71% |
20/03 | North American Morning Briefing : Markets on Hold -2- | DJ |
19/03 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Evolution of the average Target Price on Mersana Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Mersana Therapeutics, Inc.
JPMorgan Chase | |
Truist Securities | |
Wedbush | |
Guggenheim | |
Citigroup | |
Baird | |
SVB Securities LLC | |
HC Wainwright | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- MRSN Stock
- Consensus Mersana Therapeutics, Inc.